Bestor

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bestor

Quick Facts

Property Description
Active Ingredient Rosuvastatin calcium
Form Film-coated tablet
Pharmacological Class Statin (HMG-CoA reductase inhibitor)
Common Use Managing high cholesterol (Dyslipidemia)
Origin Synthetic compound

What Type of Medicine is Bestor?

Bestor is a synthetic, prescription-only pharmaceutical product classified as an antihyperlipidemic agent. Its active substance, Rosuvastatin calcium, is a highly effective member of the statin class of medicines. Statins are formally recognized as HMG-CoA reductase inhibitors. This classification confirms the medicine works by interfering with the body's internal process of cholesterol production. Rosuvastatin is clinically recognized for its high potency among available statins, meaning it can achieve significant Low-Density Lipoprotein Cholesterol (LDL-C) reduction.

Bestor's Composition and Physical Form

The core composition features the single active substance, Rosuvastatin calcium. The drug is manufactured as a film-coated tablet intended exclusively for oral administration and is designed for systemic action. The tablet form ensures the stability and standardized absorption of the active ingredient. Rosuvastatin is an established medicine used to lower blood lipids in patients with no prior history of cardiovascular events. This demonstrates the drug's long-term role in managing risk before major health issues occur.

What is the General Purpose of Bestor?

The general therapeutic purpose of Bestor is the aggressive management of unhealthy blood fat levels, a condition known as dyslipidemia. By blocking the key enzyme (HMG-CoA reductase) in the liver, the medicine systematically limits cholesterol production. This primary action results in a significant reduction of circulating Low-Density Lipoprotein Cholesterol (LDL-C), or "bad cholesterol." This effective control over the lipid profile is crucial for mitigating the vascular risk factors associated with the development of atherosclerosis and supporting the long-term primary prevention of cardiovascular disease events.

Regulatory References

  1. U.S. National Library of Medicine: MedlinePlus Drug Information

What side effects are possible with Bestor?

Possible side effects and safety information

Bestor (rosuvastatin) has an officially documented safety profile characterized by a range of adverse reactions and specific usage limitations as defined by governmental regulatory authorities (e.g., FDA, EMA).

Common Adverse Reactions (Frequency ge1/100 to <1/10): The most frequently reported side effects involve the musculoskeletal and gastrointestinal systems, and general disorders. These commonly include headache, muscle aches (myalgia), joint pain (arthralgia), nausea, constipation, stomach pain, and general weakness or fatigue (asthenia).

Serious and Clinically Significant Adverse Reactions: Regulatory sources highlight the potential for rare but serious adverse events, most notably severe muscle-related effects and liver problems.

  • Myopathy and Rhabdomyolysis: This includes muscle pain, tenderness, or weakness associated with elevated creatine kinase (CK). Rhabdomyolysis is a severe form involving muscle breakdown that can lead to acute kidney injury and, rarely, death. The risk is elevated with higher doses (e.g., 40 mg) and in patients with pre-existing kidney impairment or uncontrolled hypothyroidism.
  • Hepatotoxicity: Liver injury, including persistent elevations in liver enzymes (transaminases), and rare cases of fatal or non-fatal hepatic failure have been reported. Liver enzyme tests are often recommended before starting therapy and during treatment as clinically indicated.
  • Hypersensitivity: Rare, severe allergic reactions, including angioedema and anaphylaxis, are documented.

Safety Restrictions and Population Considerations: Bestor is formally contraindicated in several situations: in patients with known hypersensitivity to the drug, in the presence of active liver disease (including unexplained persistent elevations of serum transaminases), and during pregnancy or breastfeeding due to the potential for fetal or infant harm. Caution is advised for older patients (ge65 years), those of Asian ancestry (who may have higher systemic drug exposure), and patients with severe renal impairment, who may require a lower starting dose (e.g., 5 mg) not to exceed 10 mg. The 40 mg dose is generally restricted to patients with severe hypercholesterolemia who do not achieve their target goal on 20 mg, due to an increased risk of adverse reactions, including proteinuria and myopathy.

Overdose and Emergency Response

The regulatory information concerning an overdose of Bestor focuses primarily on mandatory management procedures rather than a defined acute symptom profile. Official regulatory labeling does not explicitly document specific acute clinical signs or symptoms within the dedicated Overdosage sections. However, the potential for severe toxicity is recognized, with high-dose exposure associated with risks to the musculoskeletal system, such as Rhabdomyolysis, and possible impact on the hepatic system.

In the event of suspected overdose, immediate medical attention is required. This urgent need for medical help applies particularly if the individual has collapsed, experienced a seizure, or cannot be awakened. Regulatory guidance explicitly mandates contacting Poison Control for the latest management instructions and procedural recommendations.

The management of a Bestor overdose is constrained by specific pharmacological realities detailed in official documentation. Regulatory documents confirm that no specific antidotes for rosuvastatin are known. Furthermore, standard procedures for drug clearance are documented as ineffective, as hemodialysis does not significantly enhance the drug's clearance from the body. Consequently, treatment must be entirely symptomatic and supportive, focusing on the patient's clinical status under professional medical supervision. No population-specific overdose notes are explicitly detailed in the official Overdosage section for populations such as pediatric or geriatric patients.

Therapeutic Uses of Bestor

What Bestor Treats: Main Uses and Benefits

Bestor is commonly used to help with the symptomatic cluster of unhealthy blood fat levels, clinically known as dyslipidemia, which is primarily characterized by elevated Low-Density Lipoprotein Cholesterol (LDL-C) and triglycerides. The therapeutic goals include addressing the overall systemic imbalance of blood fat levels. It is applied when appropriate in patients, including certain children and adolescents with severe, genetic conditions like familial hypercholesterolemia, and adults needing risk management. The core indications include managing primary hypercholesterolemia, mixed dyslipidemia, and supports general well-being in high-risk scenarios.


Quick Fact: Relief for Lipid Imbalance

Property Description
Symptom Category Systemic imbalance (Elevated LDL-C and Triglycerides)
Common Scenario Long-term management of chronic cardiovascular risk
Main Benefit Contributes to easing the overall symptom load

The medication's broader use is considered relevant in primary prevention, targeting individuals at high risk for future cardiovascular events. It helps manage the risk factors associated with atherosclerosis (plaque buildup). This strategic benefit supports patients in the long-term management of their vascular risk, which supports general well-being during the therapeutic process. “It is applied when conditions require sustained, supportive management to address symptoms related to systemic imbalance.”

Regulatory References

  1. Rosuvastatin: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Bestor?

This section describes the official population eligibility rules for Bestor (Rosuvastatin calcium) as defined by regulatory bodies.


Contraindicated Populations

Use of Bestor is contraindicated and must be avoided in several populations due to explicit regulatory mandates:

  • Active Liver Disease and unexplained, persistent elevations of liver enzymes.
  • Pregnancy and Lactation (Breastfeeding).
  • Women of Childbearing Potential not using effective contraception.
  • Severe Renal Impairment (Creatinine clearance below 30 mL/min).
  • Patients with Myopathy or those receiving Cyclosporine.

Eligibility and Restrictions by Age and Condition

Category Official Eligibility Status
Adults Approved for general use.
Pediatric Patients Approved for certain forms of familial hypercholesterolemia (starting from ages 7 or 8), but use is not recommended in children under 6 years.
Older Adults A starting dose of 5 mg is recommended for patients over 70 years old.
Moderate Renal Impairment Use is allowed, but the highest dose (40 mg) is contraindicated (CrCL < 60 mL/min).
Myopathy Risk Factors The 40 mg dose is contraindicated in patients with pre-disposing factors like uncontrolled hypothyroidism or hereditary muscular disorders.
Asian Patients A starting dose of 5 mg should be considered due to potential for increased systemic exposure.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

The official interaction profile for Bestor (Rosuvastatin) is primarily defined by agents that affect its transporter-mediated clearance and substances that carry an additive pharmacodynamic risk.

Medicinal product categories with documented interactions include immunosuppressants (e.g., Cyclosporine), Antivirals (e.g., HIV Protease Inhibitors and certain Anti-Hepatitis C Viral Agents), Fibrates (e.g., Gemfibrozil), Anticoagulants (e.g., Warfarin), and Antacids containing aluminum and magnesium hydroxide.

Interaction Classifications

Classification Official Regulatory Status
Formal Combination Prohibitions Contraindicated with certain Anti-Hepatitis C Viral Agents, such as Sofosbuvir/Velpatasvir/Voxilaprevir.
Exposure-Altering Interactions Co-administration with strong drug transporter inhibitors like Cyclosporine results in a documented, significant increase in rosuvastatin plasma concentration (AUC).
Pharmacodynamic Reinforcement Co-administration with Gemfibrozil or other fibrates increases the documented risk of myopathy and rhabdomyolysis.
Mandatory Timing Rules Aluminum and Magnesium Hydroxide Antacids require that Bestor be administered at least 2 hours prior to the antacid to prevent reduced absorption.

Population-Specific Notes

Regulatory documents note that Asian patients exhibit approximately 2-fold higher systemic exposure to rosuvastatin; this inherent characteristic may increase the severity of exposure-altering interactions documented with co-administered medicines.

Mechanism of Action

How Bestor Works

Bestor modulates activity at specific molecular targets within the liver, resulting in alterations to lipid metabolism. The mechanism involves two primary, interconnected domains: enzymatic inhibition and cellular receptor regulation.

Targeted Inhibition of Cholesterol Production

Bestor engages the mevalonate pathway by acting as a competitive inhibitor of HMG-CoA reductase, the enzyme responsible for the rate-limiting step in de novo cholesterol synthesis. This action suppresses the internal production of cholesterol in liver cells, initiating a specific intracellular feedback mechanism.

Modulation of Lipoprotein Clearance

The resulting decrease in intracellular cholesterol triggers a signaling cascade that increases the number and activity of LDL receptors on the liver cell surface. This heightened receptor expression facilitates the clearance of atherogenic lipoproteins, such as LDL-cholesterol, from the bloodstream, resulting in an alteration to the signaling patterns governing lipid homeostasis.

Dosage and Administration Information

How to Use Bestor

Bestor, which contains Rosuvastatin calcium, is administered via the oral route as a film-coated tablet and is typically used as part of a long-term management plan for chronic conditions. The tablet must be swallowed whole and can be taken once daily at any time of day, with or without food.

Official Dosing and Scheduling

Standard adult regimens typically begin with a starting dose of 10 mg or 20 mg once per day. The full approved dosage range for Bestor is 5 mg to 40 mg. The 40 mg daily dose is the maximum and is reserved only for patients with severe hypercholesterolemia who do not reach their lipid goals on the 20 mg dose.

When adjusting the dosage, a minimum interval of four weeks must be observed before increasing the dose to monitor therapeutic response.

Population-Specific Use and Administration

Dosing protocols include specific instructions for certain groups. A lower starting dose of 5 mg once daily is recommended for patients of Asian descent and for those with severe renal impairment (non-dialysis dependent). For the latter group, the dose should not exceed 10 mg daily. A 5 mg starting dose is also recommended for adults aged 70 years and older.

If a dose is missed, the protocol is to skip the forgotten dose and resume the regular schedule the following day; no attempt should be made to take an extra dose. To ensure proper absorption, Bestor must be administered at least two hours before or four hours after taking aluminum/magnesium hydroxide combination antacids.

Recent Clinical Evidence

Bestor: Recent Clinical Evidence

Clinical research for Bestor (Rosuvastatin) has primarily focused on its effect on lipid profiles and the associated risk of cardiovascular events. These trials establish the foundation for its approved use in treating high cholesterol and related conditions.


Overview of Key Findings

Major randomized, placebo-controlled trials have examined the effect of Bestor across diverse patient populations. Research consistently shows an association between the use of the drug and changes in certain blood lipid markers.

Specifically, studies observed:

  • Reduction in LDL-C (Low-Density Lipoprotein Cholesterol): Across multiple phase 3 studies, participants receiving Bestor generally recorded lower levels of 'bad' cholesterol compared to the placebo group.
  • Reduction in Triglycerides and Increase in HDL-C: Research has also explored the effect on other lipids, noting an association with decreased blood triglyceride levels and a modest increase in HDL-C ('good' cholesterol).

Cardiovascular Event Data

Long-term outcome studies investigated whether Bestor was associated with a reduced incidence of major cardiovascular events, such as non-fatal heart attack or stroke, in high-risk adult patients. Findings from these trials are critical in assessing the overall utility of lipid management in this patient group.

Study Safety Profile

Safety data collected across all phases of clinical development indicated that the drug was studied across different dose ranges. The most commonly reported adverse events in the trials included symptoms such as headache, nausea, and muscle pain (myalgia). These reported events were typically mild in intensity and often resolved without intervention. Data monitoring focused on the potential for more serious events, particularly those related to muscle or liver function.

Key Studies & References NICE Guideline: Cardiovascular disease: risk assessment and reduction, including lipid modification

Frequently Asked Questions (FAQ)

Common questions about Bestor (FAQ)

Q: How quickly does Bestor start working after I take it?

A: Studies and official information indicate that a therapeutic response from Bestor is generally observed within one week after starting therapy. The maximum reduction in cholesterol levels is typically achieved after four weeks of continuous treatment. This period allows the medicine to fully engage its mechanisms to help control lipid levels.


Q: What is the main difference between Bestor and a generic version?

A: The active ingredient in Bestor, Rosuvastatin calcium, is the same substance found in its generic version. Generic medicines approved by regulatory bodies must meet the same strict quality and effectiveness standards as the brand-name product. The main distinction is typically the brand name and commercial presentation.


Q: Is Bestor a controlled substance or habit-forming?

A: Bestor is classified as a statin, a type of medicine used to lower cholesterol. According to official drug information, Bestor (Rosuvastatin) is not designated as a controlled substance and is not considered to be habit-forming.


Q: What does it mean if Bestor has a 'contraindication'?

A: A contraindication is a condition or situation that makes the use of a medicine improper or potentially hazardous. When Bestor is contraindicated, official regulatory guidance indicates that the medicine should be avoided because the risks documented in these specific situations outweigh any potential benefits.


Q: Does the effectiveness of Bestor decrease over time?

A: Clinical data and research suggest that the maximum therapeutic response achieved by Bestor is generally maintained with continuous, long-term therapy. The medicine is designed to provide sustained inhibition of cholesterol production.


Q: Is Bestor known to interact with herbal supplements?

A: Official patient information describes the importance of informing the healthcare provider about all herbal products and supplements being used. Regulatory documents often note that the effects of co-administering Bestor with various herbal supplements may not be fully established.


Q: What should I do if a minor side effect from Bestor doesn't go away?

A: Regulatory patient information describes that any side effects or concerns, including those that are minor or persistent, should be brought to the attention of a healthcare provider for evaluation. This allows a professional to properly assess the situation.


Q: How long does Bestor stay in the body after the last dose?

A: The pharmacokinetics of Rosuvastatin, the active ingredient, show that it has an elimination half-life of approximately 19 hours. This means it takes about that long for half of the dose to be cleared from the body.


Q: Is it possible for Bestor to interact with vitamins?

A: Official regulatory documents describe the importance of informing the healthcare provider about all vitamins and minerals being taken, as a healthcare provider can evaluate potential interactions or risks.


Q: Why is Bestor not recommended for people with certain heart conditions?

A: Bestor is primarily intended to reduce the risk of future cardiovascular events, such as heart attack and stroke. The official contraindications for Bestor are related to conditions like active liver disease, myopathy, or severe kidney impairment, rather than specific existing heart conditions themselves.


Q: Does Bestor have an expiration date?

A: Yes, Bestor, like all approved medicines, is required to have an expiration date printed on the packaging. Official guidelines describe proper storage for Bestor, and indicate that unused or expired medication should eventually be disposed of through authorized programs.


Q: Does alcohol change the way Bestor works?

A: Official patient information notes that using substantial quantities of alcohol may increase the documented risk of liver-related side effects, which is a key safety concern with statins. This caution is based on documented risks to liver health.


Q: Is it normal to feel dizzy when first taking Bestor?

A: Dizziness has been noted in clinical adverse event reports associated with the use of Bestor. If an individual experiences dizziness or any other new symptoms, regulatory guidance suggests bringing it to the attention of a healthcare professional.


Q: Are there any foods or drinks to avoid while using Bestor?

A: Bestor can be taken with or without food, as there are no known specific food interactions. However, official information notes that using substantial quantities of alcohol may increase the documented risk of liver-related side effects. Also, antacids containing aluminum and magnesium hydroxide require specific timing relative to Bestor administration.


Q: How long can a person stay on Bestor?

A: Bestor is intended for continuous, long-term use as part of a management plan for chronic conditions like high cholesterol. A healthcare provider determines the appropriate duration of therapy based on the patient's individual treatment goals.


Q: Are there specific times of day that Bestor is usually taken?

A: Official guidance states that Bestor can be taken once daily at any time of the day, with or without food. The active ingredient's long duration of action supports this flexible dosing schedule.


Q: What is the difference in how Bestor and [another similar drug] affect the body?

A: Bestor is officially classified as a potent HMG-CoA reductase inhibitor, a class of drugs known as statins. While other medicines in this class share the same mechanism of action, they may differ in their potency or effect on specific cholesterol targets, as described in their regulatory profiles.


Q: What is the risk of an allergic reaction to Bestor?

A: Hypersensitivity reactions are documented in the official safety profile. These include rare but severe allergic reactions such as angioedema, which involves swelling of the face, lips, tongue, or throat, and anaphylaxis.


Q: What should be monitored by a healthcare provider while a person is on Bestor?

A: Monitoring typically involves periodic blood tests to check liver enzyme levels (transaminases). In some situations, healthcare providers may also monitor Creatine Kinase (CK) levels to assess muscle health, as part of the overall safety profile assessment.


Q: Does taking Bestor affect lab test results?

A: Yes, taking Bestor can affect certain laboratory values. Specifically, regulatory documents note documented elevations in liver enzyme levels (transaminases) and Creatine Kinase (CK) levels, which are routinely monitored during therapy.


Q: Why is the official dosage described in a range of amounts?

A: The approved dosage is described as a range to allow healthcare providers to individualize treatment. This flexibility is needed to meet specific patient lipid-lowering goals, account for risk factors, and optimize the patient's response to the drug.

How should Bestor be stored and disposed of?

How to Store and Dispose of Bestor (Rosuvastatin) Tablets

Bestor (rosuvastatin) tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medicine must be kept in its original, tightly closed container and protected from moisture and direct light; it must also be kept from freezing or exposure to excess heat.

Child Safety and Disposal

The tablets must be secured out of the sight and reach of children and pets. For disposal of unused or expired tablets, official guidelines recommend using a drug take-back program or an authorized mail-back envelope. If a take-back program is unavailable, tablets can be disposed of in household trash after being mixed with an undesirable substance. Do not dispose of the medicine by flushing it down the toilet or throwing it into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bestor found in:

A-Z Index: